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Azotemia, TNFa, and LPS prime the human neutrophil oxidative burst
by distinct mechanisms. The oxidative burst of neutrophils from azotemic
patients (A.zoPMNs) is primed for an enhanced response compared to
neutrophils from normal subjects (N0rPMNs). The mechanism for this
priming is unknown, although TNFa does not further prime AzoPMNs.
The present study examines the hypothesis that azotemia and TNFa prime
neutrophils by the same mechanism. Formyl peptide receptor expression
and degranulation were not primed in AzoPMNs, but were primed by both
LPS and TNFa. LPS was also able to prime the AzoPMN oxidative burst.
Guanine nucleotide exchange by multiple guanine nucleotide binding
proteins, including heterotrimeric G-proteins and low molecular weight
GTP-binding proteins (LMWG5), was increased in AzoPMNs, as demon-
strated by GTPyS binding and azidoanilide GTP photoaffinity labeling.
The plasma membrane density of G-protein a12, a1, and a subunits and
the density in the cytosol of the LMWG, Rac2, did not differ between
AzoPMNs and NorPMNs. However, the LMWG, RaplA, was present in
significantly greater amounts on plasma membranes from AzoPMNs.
FMet-Leu-Phe-stimulated phospholipase D activity, but not basal activity,
was significantly greater in AzoPMNs. Finally, incubation of NorPMNs in
plasma from azotemic patients resulted in a significant increase in basal
GTPyS binding. These results demonstrate that priming of AzoPMNs is
restricted to oxidative burst activity and that it occurs by a mechanism
distinct from that utilized by TNFa and LPS. While the exact mechanism
remains unknown, it appears to involve a plasma factor and changes in
LMWG expression or activity.
Polymorphonuclear leukocyte (PMN) functions have been ex-
amined extensively in patients on chronic hemodialysis primarily
for two reasons. First, an abnormal PMN function could result in
an increased susceptibility to infection, a leading cause of death in
hemodialysis patients [1, 2]. Second, alterations in PMN function
have been used as a measure of biocompatibility of hemodialysis
membranes [31. Studies examining phagocytosis and oxidative
burst of PMNs from dialysis patients have yielded variable results,
with these functions being reported as increased, normal, and
decreased [4—8]. Because the effect of azotemia, independently of
dialysis, on PMN function has received little attention, we com-
pared the ability of PMNs from non-dialyzed patients with varying
degrees of renal insufficiency (AzoPMNs) and normal individuals
(NorPMNs) to phagocytize bacteria and produce a respiratory
burst [9]. We found that phagocytosis of opsonized bacteria did
not differ between the two groups; however, AzoPMNs demon-
strated an enhanced oxidative burst stimulated by phagocytosis or
the chemoattractant, fMet-Leu-Phe, but not by phorbol myristate
acetate (PMA). The enhanced respiratory burst of stimulated, but
not resting, AzoPMNs satisfies the definition of priming. A
priming agent is defined as one that does not cause a response in
and of itself at the concentration used, but does result in an
enhanced response to subsequent stimulation with another agent
or in some cases a higher concentration of the same agent [10].
PMN responses are primed by multiple pro-inflammatory
agents, including bacterial lipopolysaccharide (LPS), granulocyte-
macrophage colony-stimulating factor (GM-CSF), interferon-y,
and tumor necrosis factor-a (TNFa) [111. Although the mecha-
nisms of priming by these agents are not well understood, recent
studies have identified increased expression of several signal
transduction components in primed PMNs. For example, priming
by GM-CSF, TNFa and LPS is associated with up-regulation of
chemoattractant receptors and chemoattractant receptor-coupled
heterotrimeric guanine nucleotide binding proteins (G proteins)
[12—171. Our previous study demonstrated that TNFa did not
alter the oxidative burst of AzoPMNs, suggesting that TNFa was
involved in the priming of AzoPMNs [9]. The present study was
initiated to compare mechanisms by which azotemia and TNFa
prime PMN responses in order to test the hypothesis that TNFa
is responsible for priming of AzoPMNs. The following questions
were addressed. (1) Are AzoPMNs refractory to priming agents
other than TNFa? (2) Is priming limited to the oxidative burst?
(3) Do TNFa and azotemia produce similar changes in PMN
signal transduction? (4) Is there a circulating factor that is
responsible for priming AzoPMNs? Our results show that
AzoPMNs are selectively refractory to priming by TNFa, that
priming of A.zoPMNs is limited to the oxidative burst, and that the
mechanism of priming in azotemia differs from that of TNFa.
Finally, incubation of NorPMNs with uremic plasma reproduced
some aspects of AzoPMN priming, suggesting that a circulating
factor is responsible.
Methods
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Reagents
Histopaque 1077 and 1119, propidium iodide, fMet-Leu-Phe,
PMA, LPS (Salmonella minnesota Re 595), cytochalasin B,
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p-nitrophenol /3-d-glucuronide, p-nitrophenol, and digitonin were
obtained from Sigma Chemical Co. (St. Louis, MO, USA).
Polymorphprep was obtained from Nycomed (Oslo, Norway).
Staphylococcus aureus of the Cowan 1 strain (Pansorbin Standard-
ized) was obtained from Behring-Calbiochem (San Diego, CA,
USA). 2 '7' -dichlorofluoresin diacetate and fluorescein conju-
gated formyl-Nle-Leu-Phe-Nle-Tyr-Lys were obtained from Mo-
lecular Probes (Eugene, OR, USA). Recombinant human TNFa
was obtained from Genzyme (Cambridge, MA, USA). GDP and
guanosine 5'-[y-thio]triphosphate (GTPyS) were obtained from
Boehringer Mannheim (Indianapolis, IN, USA). [35S]GTPyS and
rabbit sera recognizing Gas were obtained from DuPont-NEN
(Boston, MA, USA). {a-P32]azidoanilide-GTP was provided by
Dr. John Raymond (Duke University, Durham, NC, USA).
1-o-[3HjOctadecyl-sn-glycero-3-phosphocholine (lyso PAF) was
obtained from Amersham (Arlington Heights, IL, USA). 1-Mo-
noolein and phosphatidic acid (Sendary Research Laboratories,
Englewood, CA, USA) and phosphatidylethanol (Avanti Polar
Lipids Birmingham, AL, USA) were obtained for use as phospho-
lipid standards. Murine antisera recognizing Rac2 was obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit
antisera recognizing RaplA was obtained from Upstate Biotech-
nology Inc. (Lake Placid, NY, USA). Horseradish peroxidase-
conjugated goat anti-rabbit IgG and horseradish peroxidase con-jugated goat anti-mouse IgG were obtained from Vector
Laboratories (Burlingame, CA, USA). Calibrated fluorescent
microbeads (Quantum 24) were obtained from Flow Cytometry
Standards (San Juan, Puerto Rico). All buffers were prepared
from endotoxin-free water and, where practical, filtered with
endotoxin-retentive filters before use.
Subjects
AzoPMNs were obtained from 48 patients with advanced renal
insufficiency, but in whom dialysis therapy had not been initiated.
Exclusion criteria included: a history of malignancy or hemato-
logic diseases, other than the anemia of renal failure; recent
infection; and prescription of medications such as antibiotics,
corticosteroids, or immunosuppressive agents. Patients ranged in
age from 19 to 73 years (mean 49 years) and the cause of their
renal insufficiency included diabetes (18), hypertension (11),
glomerulonephritis (3), polycystic kidney disease (2), primary
acute renal failure (2), pyelonephritis (1), and unknown (11).
Their serum creatinine concentrations ranged from 2.3 to 14.4
mg/dl (mean 4.6 mg/dl) and creatinine clearances, calculated by
the method of Cockcroft and Gault [18], ranged from 6.9 to 35.4
ml/min/1.73 m2 (mean 20.6 ml/min/1.73 m2). NorPMNs were
obtained from healthy subjects. The study was approved by the
Human Studies Committee of the University of Louisville, and all
subjects gave informed consent before participating in the study.
Blood was obtained by venipuncture and collected into tubes
containing the appropriate anticoagulant for the various assays of
PMN function as described below. After needle insertion, the first
3 ml of blood was discarded to avoid components activated during
venipuncture. Blood samples were also obtained for determina-
tion of white blood cell count and differential by routine clinical
laboratory methods. In all cases, white blood cell and neutrophil
counts were in the normal range. Blood from azotemic subjects
and a normal subject were processed in parallel through the
various assays.
PMN isolation and preparation of PMN membranes and cytosol
PMNs were isolated from EDTA-anticoagulated blood by
gradient centrifugation (Histopaque 1077/1119 or Polymorph-
prep) at room temperature. The PMN layer was recovered from
the gradient and contaminating erythrocytes removed by hypo-
tonic lysis. The PMNs were then washed and resuspended in the
appropriate buffer.
PMN membrane and cytosol fractions were prepared by resus-
pending isolated PMNs in sucrose buffer (250 m sucrose, 20 mM
Tris/HC1 (pH = 7.4), 1.5 mi MgC12, 10 mvi EGTA, 2 mrvi EDTA,
1 g/ml aprotinin, 1 tg/ml antipain, 1 m'vi benzamidine, 1 jtg/ml
chymostatin, 2 LM leupeptin, 1 .tg/ml pepstatin A, 4 jg/ml
soybean trypsin inhibitor, 500 tM PMSF) and disrupting the cells
with sonication at 4°C. After removing undisrupted cells and
nuclei by centrifugation at 2000 x g for one minute, the remaining
lysate was subjected to centrifugation at 28,000 X g for 15 minutes
at 4°C. The supernatant, representing PMN cytosol, was snap
frozen in liquid nitrogen and stored at —70°C. The pellet,
representing PMN membrane, was washed three times in ice-cold
storage buffer (20 mivi Tris/HC1 (pH = 7.4), 1 mM EDTA, 1 mM
DTT, 3 mvi benzamidine, 1 mivi PMSF, 10 /.M leupeptin, and 2
ig/ml soybean trypsin inhibitor), aliquoted, snap frozen in liquid
nitrogen, and stored at —70°C.
Phagocytosis and H202 production
Phagocytosis of S. aureus and the subsequent production of
H202 was measured in ACD-anticoagulated whole blood by a
flow cytometric assay as previously described [9, 19].
Formyl peptide receptor expression
The expression of formyl peptide receptors was determined
using fluorescein conjugated formyl-Nle-Leu-Phe-Nle-Tyr-Lys
(FLPEP) and flow cytometry as described by Sklar et al [201.
Isolated PMNs (2 X 106 cells/mi) were incubated with 5 nM
FLPEP at 4°C for 30 minutes. Non-specific binding was measured
by including 1 M fMet-Leu-Phe in the incubation mixture. Bound
FLPEP was determined by flow cytometry using an Epics Profile
II flow cytometer (Coulter, Hialeah, FL, USA). PMNs were
selectively gated for analysis on the basis of forward versus right
angle light scatter and light emission was measured on 5000 PMNs
per sample. Specific binding of FLPEP was calculated by subtract-
ing the mean channel number of fluorescence intensity obtained
in the presence of 1 LM fMet-Leu-Phe from that obtained with
FLPEP alone. The number of FLPEP binding sites was calculated
using calibrated fluorescent microbeads. The flow cytometer was
calibrated before analysis of each set of samples with Standard-
Brite beads (Coulter).
Degranulation
Degranulation was assessed by measuring the release of -gluc-
uronidase from primary granules as previously described [21].
Briefly, isolated PMNs (5 X 107/ml) were resuspended in buffer
containing calcium and magnesium and incubated with 5 tg/ml
cytochalasin B at 37°C for five minutes. Degranulation was then
stimulated by the addition of 1 jig/ml PMA, 5 X iO opsonized S.
aureus, or 10 l.tM fMet-Leu-Phe for 30 minutes at 37°C. The
reaction was stopped by rapid cooling to 4°C followed by imme-
diate centrifugation to remove the PMNs. f3-glucuronidase activity
in the supernatant was determined by measuring the release of
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p-nitrophenol from p-nitrophenol p-d-glucuronide [21]. One hun-
dred microliters of 0.01 M p-nitrophenol /3-d-glucuronide was
added to tubes containing 500 1.d of 0.5 M sodium acetate buffer
(pH = 5.0), 100 1sl of 1% Triton X-100, and 300 pA of the
supernatant from the degranulation reaction. After incubation at
37°C for one hour, the reaction was stopped by the addition of 1
ml of ice cold 0.2 M NaOH. The absorbance of the reaction
mixture was read at 400 nm and the /3-glucuronidase activity
quantitated using a standard curve constructed using known
concentrations of p-nitrophenol.
TNFa and LPS priming
The ability of TNFa and LPS to prime phagocytosis and H202
production, formyl peptide receptor expression, and degranula-
tion was assessed by incubating whole blood with and without
TNFa (200 lU/mi for 10 mm) or LPS (100 ng/mI for 60 mm). We
have shown previously that these conditions provide maximal
priming of PMN oxidative burst activity [22, 231, and they were
used in this study to minimize the possibility of a false negative
result with AzoPMNs. Phagocytosis and H202 production were
then determined in whole blood as described above. Formyl
peptide receptor expression and degranulation were determined
as described above after PMN isolation.
GTPyS binding
GTPYS binding was determined in digitonin-permeabilized
PMNs as previously described [241. Briefly, a reaction mixture
(160 pA) containing 150 mt NaC1, 1 m'vi EDTA, 5 mrvi MgCI2, 50
mM triethanolamine/HC1 (pH = 7.4), 10 /.LM digitonin, I JLM GDP,
10 nM GTPyS, 0.02 to 0.04 jCi [35SJGTPyS, and fMet-Leu-Phe at
the desired concentration was warmed for five minutes at 30°C.
The binding reaction was started by the addition of 10° PMNs and
the incubation continued for a further 30 minutes. The reaction
was terminated by the addition of 2.5 ml of ice-cold buffer
containing 50 mM triethanolamine/HC1 and 5 mrvi EDTA, fol-
lowed by rapid filtration through nitrocellulose. The filters were
washed with four additional 2.5 ml volumes of ice-cold buffer and
counted in a liquid scintillation spectrometer. Specific binding was
calculated as fmol GTPyS bound per 10° cells by subtracting
[35S]GTPyS bound in the presence of 10 /LM GTPYS from the
total [35S]GTPyS bound.
Photoaffinity labeling of GTP binding sites
Binding of the photoaffinity label, [a-P32] azidoanilide-GTP
(AA-GTP), was determined in permeabilized PMNs by a modifi-
cation of the method described above. A reaction mixture (120 pl)
containing 150 mM NaC1, 1 mi EDTA, 5 mi MgC12, 50 mM
Triethanolamine/HC1 (pH = 7.4), 10 jM digitonin, 0.1 /.LM GDP,
[a-P32]AA-GTP (2 Ci per tube) and buffer or 10 jIM fMet-Leu-
Phe was warmed for five minutes at 30°C. PMNs (2 X 10° cells)
were added and the incubation continued for a further 20
minutes. The tubes were then placed in an ice slurry and exposed
to short wave length UV light (254 nm) for three minutes.
Following the addition of 100 1.d of Laemmli's buffer and boiling,
the labeled proteins were separated by 10% SDS-PAGE. The
labeled proteins were quantitated by phosphor screen autoradiog-
raphy (Phosphor Imager:SF; Molecular Dynamics, Sunnyvale,
CA, USA).
Immunoblotting
Immunoblot analysis was used to determine the quantity of
specific G proteins or G protein subunits present in PMN
membrane or cytosol. Briefly, equal amounts of membrane or
cytosol protein were solubilized in Laemmli's sample buffer,
subjected to 10% SDS-PAGE, and transferred electrophoretically
to nitrocellulose membranes. Antisera identifying a12 and a11 were
produced in rabbits using the synthetic peptides KENLKDCGLF
and KNNLKECGLY, respectively, and used at a 1:5000 dilution.
The other primary antibodies used were polycional antisera which
recognize as (used at 1:5000 dilution), Rac2 (used at a 1:500
dilution), and RaplA (used at a 1:500 dilution). Antibody was
detected by either horseradish peroxidase-conjugated goat anti-
rabbit IgG or goat anti-mouse IgG diluted 1:5000 and detected by
ECL enhanced chemiluminescence (DuPont-NEN). The bands of
interest were quantitated by densitometiy using ImageQuaNT
software (Molecular Dynamics, Sunnyvale, CA, USA).
Phospholipase D
Phospholipase D activity was determined by measuring the
formation of phosphatidylethanol [251. Briefly, isolated PMNs (5
x 10°/ml) were incubated in phenol red-free RPMI 1640 contain-
ing 25 mt HEPES and 10 jtCi [3H] lyso PAF at 37°C for 75
minutes. Cytochalasin B (5 ig/ml) was added, followed five
minutes later by ethanol (0.5% vol/vol) and the incubation
continued for a further five minutes. The cells were then stimu-
lated by the addition of fMet-Leu-Phe (10—s M) or buffer. The
reaction was stopped after three minutes by the addition of 3.75
ml acidified methanol/chloroform (2:1) and the tubes placed in an
ice slurry for 30 minutes. Lipids were recovered by adding 1.25 ml
each of chloroform and water and isolating the organic phase by
centrifugation at 700 X g for five minutes at 4°C [26]. After
removing the organic phase, the aqueous phase was washed a
second time with chloroform. The organic phases were combined,
dried under nitrogen, and reconstituted in 100 j.d of chloroform/
methanol (9:1 vol/vol). The reconstituted samples and phospho-
lipid standards were spotted onto silica gel 60 plates (EM Science,
Gibbstown, NJ, USA) and the plates developed in chloroform/
methanol/acetic acid (65:15:6 vol/vol/vol). Lipids were visualized
with iodine, spots corresponding to phosphatidylethanol standard
(Rf = 0.7) were scraped into scintillation vials, and radioactivity
determined by liquid scintillation spectroscopy.
Effect of azotemic plasma on GTPyS binding in NorPMNs
Heparinized plasma was obtained from patients with azotemia
(creatinine clearance 11.6 to 29.9 ml/min/1.73 m2) or normal
control subjects. Isolated NorPMNs, at a concentration of 1 x i0
cells/mI, were incubated at 37°C in the presence of 5% CO2 for 60
minutes in I ml azotemic plasma or heterologous normal plasma.
The plasma was separated from cells by centrifugation and
GTPyS binding determined in permeabilized PMNs in the pres-
ence and absence of 30 jIM fMet-Leu-Phe as described above.
Data analysis
Data are presented as mean SD for the N of observations.
Analysis of variance was used to compare AzoPMNs and
NorPMNs and unstimulated and stimulated responses. Where the
data were found to be not normally distributed, equivalent
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Table 1. Effect of LPS on phagocytosis and H202 production in normal
and azotemic neutrophils
Norm
(N
al PMN
= 12)
LPS
Azotemic PMN
(N 15)
LPS
Control 100 ng/ml Control 100 ng/ml
Phagocytosis 15.2 5.6 18.9 5.4 19.1 4.9 22.7 4.6
H202
Basal 1.22 0.30 2.41 0.67 1.52 0.38 3.11 0.96
Phagocytosis- 67 20 99 29° 108 29h 143 37°
stimulated
Results are presented as mean SD for N observations.
a Incubation with LPS increased stimulated H202 production signifi-
cantly in both azotemic PMN5 and in normal PMNs (P < 0.001)
"In the absence of LPS, stimulated H202 production by azotemic PMNs
was significantly greater than by normal PMNs (P < 0.001)
non-parametric tests were used. All statistical testing was per-
formed using SigmaStat (Jandel Scientific, San Rafael, CA, USA).
Results
In our previous study, we demonstrated that the phagocytosis-
stimulated oxidative burst by AzoPMNs is not primed by incuba-
tion with TNFa [9]. To determine if AzoPMNs were refractory to
priming by agents other than TNFa, the ability of LPS to prime
the phagocytosis-stimulated oxidative burst response of
AzoPMNs was measured. The data in Table 1 confirm our
previous finding that phagocytosis-stimulated H202 production
was significantly greater in AzoPMNs than NorPMNs in the
absence of LPS pretreatment, while phagocytosis did not differ
[91. A one hour exposure to 100 nglml LPS significantly enhanced
phagocytosis-stimulated H202 production to a similar degree in
AzoPMNs and NorPMNs, while phagocytosis did not differ
significantly. Thus, AzoPMNs are not refractory to all priming
agents.
To determine if multiple responses of PMNs were primed in
azotemia or if priming was limited to the oxidative burst, degran-
ulation in NorPMNs and AzoPMNs and the ability of TNFa and
LPS to enhance this degranulation were examined. Degranulation
stimulated by fMet-Leu-Phe, opsonized S. aureus, and PMA was
determined by measuring release of f3-glucuronidase, which is
present in primary granules [27]. Table 2 shows that there was no
significant difference in -glucuronidase release between
AzoPMNs and NorPMNs following treatment with any of these
stimuli. FMet-Leu-Phe-stimulated 13-glucuronidase release was
enhanced to a similar extent in AzoPMNs and NorPMNs by
incubation for 60 minutes with 100 ng/ml LPS (62 38% and 53
33% increase in -glucuronidase release in AzoPMNs and
NorPMNs, respectively, N 3) or by incubation for 10 minutes
with 200 U/mI TNFa (48 27% and 44 6% increase in
p-glucuronidase release in AzoPMNs and NorPMNs, respectively,
N = 3).
The above results showing that the oxidative burst of AzoPMNs
is refractory to priming by TNFa, but not LPS, suggested that
azotemia and TNFa share a common mechanism of priming.
Based on the ability of azotemia to increase PMN responses to the
chemoattractant, fMet-Leu-Phe [9] and the ability of TNFa to
increase membrane expression of chemoattractant receptors [28],
the expression of formyl peptide receptors in the basal state and
Table 2. /3-Glucuronidase release by azotemic and normal PMN before
and after stimulation with phorbol myristate acetate, fMet-Leu-Phe, and
opsonized Staphylococcus aureus
/3-Glucuronidase release
nmol/107 cells/mm
Azotemic Normal
PMN PMN
Unstimulated 0.091 0.019 0.085 0.025
PMA 1 jrg/ml
fMet-Leu-Phe
S aureus (5 ><
10 pw
105/ml)
0.303 0.058° 0.282 0.042°
0.427 0.077a 0.389 0.058°
0.275 0.085° 0.250 0.044°
Data are presented as mean SD for 8 experiments. There was no
difference in /3-glucuronidase release between azotemic and normal PMN
(N = 0.114).aAll three stimuli increased /3-glucuronidase release compared to
unstimulated cells (P < 0.05)
Table 3. Formyl peptide receptor expression by unstimulated PMN,
and after stimulation with LPS (100 ng/ml for 60 mm at 37°C) and
TNFa (200 U/ml for 10 mm at 37°C)
Formyl peptide receptors per cell
Azotemic Normal
PMN PMN
Unstimulated 13600 4890 11300 6070
LPS 100 ng/ml for 60 mm 28200 11900° 27400 12990°
TNFa 200 U/mI for 10 mm 32900 6230° 29600 9930°
Data are presented as mean SD for 12 observations (basal and
LPS-stimulated) or 5 observations (TNFa-stimulated). There was no
difference in formyl peptide receptor expression between unstimulated
azotemic and normal PMN.
aPrior incubation with LPS and TNFa significantly increased formyl
peptide receptor expression, and to the same extent, in both azotemic and
normal cells (P < 0.05 compared to unstimulated)
after TNFa and LPS exposure was examined in AzoPMNs and
NorPMNs. As shown by the data in Table 3, no difference in the
basal number of formyl peptide receptors between unstimulated
AzoPMNs and NorPMNs was observed. A 60 minute incubation
with 100 ng/ml LPS or a 10 minute incubation with 200 U/mi
TNFa significantly increased the expression of formyl peptide
receptors to a similar degree in AzoPMNs and NorPMNs. Thus,
up-regulation of formyl peptide receptors is not a mechanism of
priming in AzoPMNs.
We previously reported that priming of human PMNs by TNFa
is associated with increased basal and fMet-Leu-Phe-stimulated
GTPYS binding resulting from increased membrane expression of
G protein a12 and a13 subunits [23], G proteins known to be
coupled to chemoattractant receptors [29, 30]. To determine if
chemoattractant receptor-coupled G proteins were increased in
azotemia, basal and f-Met-Leu-Phe-stimulated GTPYS binding
were measured in permeabilized AzoPMNs and NorPMNs. As
shown in Figure 1, both basal and stimulated GTPyS binding were
significantly greater in AzoPMNs. However, the magnitude of the
increase in GTPYS binding following fMet-Leu-Phe stimulation
was similar in the two groups, indicating that the difference in
stimulated GTP7S binding between AzoPMNs and NorPMNs
could be accounted for solely by the difference in basal binding.
The results of the degranulation experiments, formyl peptide
receptor expression, and GTPyS binding indicate that neither
fMLP concentration, iM
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Fig. 1. Dose response of fMet-Leu-Phe-dependent GTPyS binding in per-
meabilized PMN from azotemic (U) and normal (•) subjects. Data are
presented as mean SD for 8 experiments. GTPyS binding was signifi-
cantly greater in azotemic PMN than in normal PMN (P < 0.0001).
GTPYS binding increased significantly with increasing concentrations of
fMet-Leu-Phe (P = 0.0107); however, the magnitude of this increase did
not differ between azotemic and normal PMN (P = 0.979).
LPS nor TNFa is the priming agent in azotemia, and that the
mechanisms of priming by TNFa and azotemia differ.
To identify GTP-binding proteins that might account for in-
creased basal GTPyS binding, permeabilized PMNs were sub-
jected to photoaffinity labeling with AA-GTP in the presence and
absence of io— M fMet-Leu-Phe, and the labeled proteins
separated by SDS-PAGE. As shown in Figure 2 and Table 4,
proteins at four distinct molecular sizes (20 to 25 kDa, 40 kDa, 55
kDa, and 60 kDa) demonstrated significantly increased AA-GTP
labeling in AzoPMNs compared to NorPMNs. While stimulation
with fMet-Leu-Phe resulted in a significant increase in AA-GTP
labeling of all these proteins in NorPMNs, fMet-Leu-Phe failed to
increase labeling of any of these proteins in AzoPMNs.
As both heterotrimeric G proteins and ras-related low molec-
ular weight GTP-binding proteins (LMWG) are involved in the
PMN respiratory burst response [31], increased AA-GTP labeling
and GTPyS binding by AzoPMNs suggest the possibility that
azotemia primes PMNs by increasing the expression of one or
more of these GTP-binding proteins. The proteins identified by
photoaffinity labeling at 40 kDa likely represent a12 and a3
subunits of heterotrimeric G proteins. To determine if AzoPMNs
demonstrated increased expression of these, or other, heterotri-
meric G proteins, specific proteins were quantitated by immuno-
blotting of PMN membranes. As shown by the data in Figure 3
and Table 5, there was no difference in the density of a12, a3, or
the two isoforms of a. between NorPMNs and AzoPMNs. The
AA-GTP-labeled proteins between 20 and 25 kD likely represent
LMWGs. Two LMWGs, Rac2 and RaplA, are known to partic-
ipate in activation of the respiratory burst. Rac2 is a cytosolic
LMWG required for association and activation of membrane and
cytosolic NADPH oxidase components [32—34]. Immunoblotting
of cytosol showed that the expression of Rac2 did not differ
between NorPMNs and AzoPMNs (Fig. 3 and Table 5). RaplA is
associated with the cytochrome b558 membrane component of
NADPH oxidase and is required for NADPH oxidase activation
20 kDa —
Fig. 2. SDS-PAGE showing the binding of the photoajJinity label,
[a-F°2Jazidoanilide-GTP (AA-GTP), to different molecular sized proteins in
permeabilized normal (lanes I and 2) and azotemic (lanes 3 and 4) PMNs.
AA-GTP binding was determined in unstimulated cells (lanes 1 and 3) or
in the presence of 10 zM fMet-Leu-Phe (lanes 2 and 4). The data are
representative of 9 experiments, and quantitative data for all experiments
are summarized in Table 4.
Table 4. Photoaffinity labeling of GTP binding sites in permeabilized
PMN with [aP32}azidoanilide-GTP
.
Binding
site
Azidoanilide-GTP bound arbitray density units/2 X 106 cells
Unstimulated fMet-Leu-Phe 10 p.M
Azotemic Normal Azotemic Normal
20—25 kDa 135 26 69 15 144 30 167 37b
40 kDa 172 33 102 35 143 27 232 97"
55 kDa 87 25 32 11 94 27 98 22"
60 kDa 96 22 52 20 105 45 100 41"
Data are presented as mean SEM for 9 experiments.
In unstimulated cells, AA-GTP binding was significantly greater in
azotemic PMNs than in normal PMNs (P < 0.025)
AA-GTP binding increased significantly in response to fMet-Leu-Phe
in normal PMNs (P < 0.05), but remained unchanged in azotemic PMNs
[35, 361. Figure 3 and Table 5 show that membranes from
AzoPMNs contain significantly more RaplA than membranes
from NorPMNs. The identity of the higher molecular size GTP-
binding proteins is not known. These proteins did not co-migrate
with eIF-2, eEF-Tu, and eIF-2B (purified proteins provided by
Dr. Jaydev Dholakia, University of Louisville), GTP-binding
proteins involved in protein synthesis (data not shown).
If the increased guanine nucleotide exchange of heterotrimeric
G proteins and LMWGs in AzoPMNs demonstrated by photoaf-
finity and GTPyS binding experiments contributes to increased
oxidative burst activity, we postulated that effector enzyme acti-
vation should be enhanced as well. Therefore, unstimulated and
ii)
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f-Met-Leu-Phe + +
60 kDa —
40 kDa —1 3 10 30
1
Azotemic Normal
Fig. 3. Immunoblots showing amounts of heterotrimeric G-protein subunits (a0, a0, a) and low molecular weight G-proteins (Rac2, RaplA) in the plasma
membrane (a a15 a, RaplA) or cytosol (Rac2) of azotemic and normal PMNs. Immunoblots are representative of 2 to 3 experiments and quantitative
data for all experiments are summarized in Table 5.
fMet-Leu-Phe-stimulated phospholipase D activities were com-
pared between NorPMNs and AzoPMNs. As shown in Table 6,
basal phospholipase D activity did not differ between NorPMNs
and AzoPMNs. On the other hand, fMet-Leu-Phe stimulated a
significantly greater increase in phospholipase D activation in
AzoPMNs than in NorPMNs.
To determine if a plasma factor induced the changes seen in
AzoPMNs, NorPMNs were incubated in plasma from azotemic
patients or in heterologous normal plasma for 60 minutes at 37°C
and GTPYS binding measured in permeabilized cells. Exposure to
plasma from azotemic patients resulted in a significant increase in
basal GTPYS binding (245 62 vs. 329 58 fmol/106 cells,
normal vs. azotemic plasma, P = 0.003, N = 10).
Discussion
We reported previously that phagocytosis-stimulated H202
production was significantly greater in AzoPMNs than NorPMNs,
and that TNFa was unable to further prime this response [91. To
assess whether TNFa might be the priming agent in azotemia, one
goal of the current study was to determine whether AzoPMNs
were refractory to other priming agents or only refractory to
TNFa. To accomplish this goal, the ability of LPS to prime
phagocytosis-stimulated oxidative burst activity was compared
between AzoPMNs and NorPMNs. The current study again shows
that AzoPMNs have a significantly increased oxidative burst
response, while phagocytosis did not differ between AzoPMNs
and NorPMNs. LPS was able to prime phagocytosis-stimulated
H202 production similarly in AzoPMNs and NorPMNs, while the
level of phagocytosis was not enhanced. As not all priming agents
were tested, we cannot state that AzoPMNs are refractory to
priming only by TNFa. However, our results indicate that
AzoPMNs are not refractory to priming. The failure of TNFa, but
not LPS, to prime AzoPMNs could result from competition for
binding of TNFa by soluble TNFa receptors. These soluble
I I I
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Table 5. Amounts of specific GTP-binding proteins in membrane and
cytosol of azotemic and normal PMN as determined by immunoblot
GTP-binding protein N Source
Amount of protein
(arbitrary density units)
Azotemic PMN Normal PMN
02 8 Membrane 2.18 0.54 2.03 0.81
03 4 Membrane 0.90 0.43 0.68 0.33
a (43 kDa) 4 Membrane 2.31 0.66 2.66 0.52
(45 kD) 4 Membrane 1.30 0.21 1.16 0.30
Rac2 9 Cytosol 0.58 0.29 0.51 0.28
RaplA 5 Membrane 0.68 0.18a 0.36 0.18
Data are presented as mean SD for N observations.
a The membrane of azotemic PMNs contained significantly more
RaplA than the membrane of normal PMNs (P = 0.032)
receptors accumulate in the plasma of patients with renal insuf-
ficiency [37—39], and we have shown that the ability of TNFa to
prime oxidative burst activity in NorPMNs is reduced in the
presence of azotemic plasma containing high levels of soluble
TNFa receptors [39]. However, since we found that TNFa
up-regulated formyl peptide receptors and primed degranulation
in AzoPMNs, it is unlikely that soluble TNFa receptors are
responsible for the failure of TNFa to prime oxidative burst
activity in AzoPMNs.
One factor that potentially may contribute to the enhanced
oxidative burst response in AzoPMNs is the frequent use of
antihypertensive drugs in patients with chronic renal insufficiency.
The most common drugs used in our patients were the calcium
channel antagonist, nifedipine (44% of patients) and various
angiotensin converting enzyme (ACE) inhibitors (25% of pa-
tients). Previous studies have shown that calcium channel antag-
onists impair PMN oxidative burst activity, albeit at suprathera-
peutic doses [40, 41], while ACE inhibitors have no effect on PMN
oxidative burst activity [42]. Thus, it is unlikely that the enhanced
oxidative burst observed in AzoPMNs arises from the use of
antihypertensive drugs.
A second goal of this study was to determine if the oxidative
burst activity is selectively primed in azotemia, or if other PMN
responses are also enhanced. To accomplish this goal, degranu-
lation stimulated by fMet-Leu-Phe, opsonized S. aureus, and
PMA was measured, and the ability of TNFa and LPS to prime
this response was determined. Degranulation did not differ be-
tween AzoPMNs and NorPMNs, and pretreatment with TNFa
and LPS resulted in enhanced fMet-Leu-Phe-stimulated degran-
ulation. Thus, priming associated with azotemia appears limited
to oxidative burst activity. These data also exclude both TNFa and
LPS as the agents responsible for priming the oxidative burst in
azotemia.
A third goal was to determine if priming in azotemia and by
TNFa produced similar changes in PMN signal transduction
pathways. The signalling pathways utilized to activate the oxida-
tive burst are incompletely identified. Therefore, the precise
mechanisms of priming by TNFa are unknown. One possible
mechanism is the up-regulation of receptors capable of stimulat-
ing the PMN oxidative burst response. TNFcs, LPS, and GM-CSF
have all been reported to alter the number or affinity of formyl
peptide receptors [12, 15, 16]. However, our data indicate that
formyl peptide receptor expression is not increased in AzoPMNs,
while both TNFa and LPS are able to up-regulate expression of
Table 6. Phospholipase D activity in azotemic and normal PMNs
before and after stimulation with fMet-Leu-Phe
Phospholipase D Activity
dpm phosphatidylethanol/4 X 1O cells
Azotemic PMN Normal PMN
Unstimulated 510 246 485 202
fMet-Leu-Phe 1 jzw 1274 303 1040 352
Data are presented as mean SD for 6 experiments. There was no
difference in phospholipase D activity between unstimulated azotemic and
normal PMNs (P = 0.5175).aStimulation with fMet-Leu-Phe resulted in a significantly greater
increase in phospholipase D activity in azotemic PMNs than in normal
PMNs (P = 0.0091)
these receptors in NorPMNs and AzoPMNs. Although we did not
directly measure the expression of receptors for phagocytosis, the
equivalent phagocytosis in NorPMNs and AzoPMNs suggests that
immunoglobulin Fe and complement receptors were not different.
We recently showed that TNFa-induced priming is associated
with increased membrane expression of the chemoattractant
receptor-associated G proteins, G12 and G3, increased basal and
fMet-Leu-Phe-stimulated guanine nucleotide exchange, and en-
hanced phospholipase D activity stimulated by direct activators of
G proteins [23]. In the present study, basal GTPyS binding was
increased in Az0PMNs; however, the ability of fMet-Leu-Phe to
stimulate increased GTPyS binding was not different between
AzoPMNs and NorPMNs. Additionally, membrane density of 0i2
and a13 did not differ between AzoPMNs and NorPMNs. Thus,
there are distinct differences in azotemia- and TNFa-induced
expression of signal transduction components. Our results suggest
that the mechanism of priming associated with azotemia differs
from that of TNFa, despite the inability of TNFa to further prime
oxidative burst activity in AzoPMNs. The failure of TNFa to
prime oxidative burst activity of AzoPMNs may result from TNFa
and azotemia activating separate priming pathways to enhance the
response of a common distal pathway leading to an increased
NADPH oxidase response. The ability of LPS to prime oxidative
burst activity in AzoPMNs indicates that LPS, TNFa and
azotemia each utilize separate mechanisms to prime PMN oxida-
tive burst activity.
The increased basal GTPyS binding in AzoPMNs in the
absence of increased heterotrimeric G protein expression sug-
gested that either increased LMWG expression or altered guanine
nucleotide exchange occurred in azotemia. Photoaffinity labeling
with AA-GTP was performed to screen for differences in GTP
binding protein expression between NorPMNs and AzoPMNs.
Proteins at four different molecular sizes (60 kDa, 55 kDa, 40
kDa, and 20 to 25 kDa) were photoaffinity labeled in NorPMNs.
Surprisingly, fMet-Leu-Phe stimulated increased AA-GTP label-
ing of all these proteins, not just heterotrimeric G protein a
subunits at 40 kDa. AA-GTP binding to all four groups of proteins
was increased in AzoPMNs, and fMet-Leu-Phe failed to stimulate
a further increase in this labeling. The identity of the proteins at
60 and 55 kDa is unknown. The proteins at 40 kDa and between
20 and 25 kDa likely represent the heterotrimeric G protein
subunits, a and 03 and ras-related LMWGs, respectively. The
quantity of some LMWGs was examined by immunoblot analysis
of either PMN membranes or cytosol. LMWGs of the Rap and
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Rho subfamilies participate in signalling pathways leading to
oxidative burst activation. Rac2, a member of the Rho subfamily,
is a cytosolic LMWG required for NADPH oxidase enzyme
assembly in human PMNs [32—341. Therefore, the quantity of
cytosolic Rac2 was determined by immunoblotting and did not
differ between AzoPMNs and NorPMNs. Activation of Rac2
results in its translocation from cytosol to plasma membrane. As
we did not examine the relative distribution of Rac2 between
cytosol and membrane, it is possible that differences in total cell
content were undetected. RaplA is a membrane-bound LMWG
that complexes with cytochrome b558, a component of the
NADPH oxidase complex, and is required for NADPH oxidase
activation [35, 36]. Immunoblot analysis demonstrated that mem-
branes from AzoPMNs contained about twice the RaplA as
membranes from NorPMNs. Although increased RaplA expres-
sion may contribute to enhanced respiratory burst activity, RaplA
expression cannot fully account for differences in basal GTPyS
binding and AA-GTP photoaffinity labeling. The increased
GTPyS binding and photoaffinity labeling of multiple proteins in
AzoPMNs suggests that azotemia stimulates increased guanine
nucleotide exchange by many, if not all, GTP binding proteins.
To determine if increased guanine nucleotide exchange could
contribute to enhanced PMN responses, basal and fMet-Leu-Phe-
stimulated phospholipase D activity were measured. As two
LMWGs, ARF and Rho, regulate phospholipase D activation
[43—45], we postulated that increased guanine nucleotide ex-
change in azotemia would result in increased phospholipase D
activity. While phospholipase D activity was not different in
unstimulated AzoPMNs and NorPMNs, fMet-Leu-Phe-stimu-
lated phospholipase D activity was significantly greater in
AzoPMNs than NorPMNs. Omann and colleagues have postu-
lated that a threshold level of heterotrimeric G protein activation
is required to transduce chemoattractant-stimulated PMN re-
sponses [46]. Thus, the failure of basal phospholipase D activity to
differ between NorPMNs and AzoPMNs may be explained by a
requirement for a threshold level of heterotrimeric G protein and
LMWG activation before phospholipase D activity is increased. In
the basal state, heterotrimeric G protein and LMWG activation in
AzoPMNs may be closer to the threshold required for phospho-
lipase D activation, leading to an enhanced phospholipase D
response. Although the biologic significance of the difference in
phospholipase D activity between AzoPMNs and NorPMNs was
not addressed in this study, the changes in phospholipase D
activity we observed in response to fMet-Leu-Phe are similar to
those reported by other investigators [47], and the enhanced
response seen in AzoPMNs is similar in magnitude to that seen
following priming with TNFs [47]. Thus, our results suggest the
possibility that increased guanine nucleotide exchange in
azotemia may result in enhanced effector enzyme responses to
stimulation, and therefore, may contribute to differences in func-
tional responses.
Although the contribution of either increased RaplA expres-
sion or altered guanine nucleotide exchange to the enhanced
responses of AzoPMNs remains to be established, either of these
events could lead to enhanced PMN oxidative burst activity.
RaplA is necessary for NADPH oxidase activation in intact cells,
but not in cell-free systems [35, 36, 48]. As RaplA associates with
cytochrome b558, an increase in RaplA expression may indicate
an increase in the membrane components of the NADPH oxidase.
If expression of the membrane components is limiting to oxidase
activation, increased expression of cytochrome b558 would lead to
an enhanced response to a given stimulus. On the other hand, a
generalized increase in guanine nucleotide exchange in azotemia
could alter the signal transduction pathways leading to NADPH
oxidase activation at several points. Heterotrimeric G proteins
couple chemoattractant receptors to effector pathways, while
LMWGs participate in more distal points of these signal path-
ways. For example, Rho and ARF regulate the activation of
phospholipase D [43, 44, 45] and Rac2 is required for NADPH
oxidase activation in both intact cells and cell-free systems [32, 33,
34, 49]. Increased basal activity of heterotrimeric G proteins and
LMWGs because of enhanced guanine nucleotide exchange could
result in a greater response in stimulated PMNs. Further studies
will be required to determine if either of these postulated schemes
contributes to priming in azotemia.
The final goal of this study was to determine if a circulating
factor was responsible for the differences between AzoPMNs and
NorPMNs. We demonstrate that azotemic plasma contains a
factor that alters GTPYS binding within an hour of exposure to
NorPMNs. Our data are consistent with the report of Rhee,
McGoldrick and Meuwissen [50] that identified a low molecular
weight factor (< 1000 Da) in the serum of patients with renal
insufficiency that enhanced oxidative burst activity of NorPMNs.
Although the identity of this factor remains to be determined, the
isolation of such a factor may provide a significant advance in
identifying uremic toxins.
In conclusion, priming of PMNs in uremia is restricted to
oxidative burst activity. Other functions, including chemoattrac-
tant receptor expression, phagocytosis, lysosomal enzyme release,
and the ability of TNFcs and LPS to prime these responses, are
similar in AzoPMNs and NorPMNs. The clinical consequences of
enhanced PMN oxidative burst responses in patients with
azotemia remain to be established. Voncken et al [51] recently
reported that mutant mice with PMNs that demonstrated an
enhanced oxidative burst response and enhanced priming during
infection were more susceptible to PMN-induced tissue injury and
septic shock during gram negative infections. These results may
provide an explanation for the increased morbidity and mortality
from infection in patients with renal insufficiency. It is also
possible that PMNs primed by azotemia contribute to progression
of chronic renal disease. Previous studies have shown that injec-
tion of primed PMNs into the renal artery can reduce GFR under
some conditions [52, 53].
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